Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS) will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 2:30 pm ET. Key executives, including President & CEO William Collier and Chief Scientific Officer Dr. Michael Sofia, will present. A live webcast is available on the company’s website, and an archived replay will follow. Arbutus focuses on discovering therapeutics for viral diseases, particularly Hepatitis B and SARS-CoV-2, with ongoing phase 2 trials for its lead compound AB-729.
- None.
- None.
WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference taking place in New York on Tuesday, October 4, 2022 at 2:30 pm ET.
Presenters: William Collier, President & Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Offer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
A live webcast of the fireside chat can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine to provide a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When is Arbutus Biopharma's fireside chat at Chardan’s conference?
Who will present at Arbutus Biopharma's event?
How can I access the webcast of the Arbutus fireside chat?
What is the focus of Arbutus Biopharma's research?
What is the significance of AB-729 for Arbutus Biopharma?
